Crescent Biopharma rises as global trial for new cancer drug starts
ReutersFeb 18, 2026 5:00 PM
Shares of drugmaker Crescent Biopharma CBIO.O rise 4% to $9.68
Co says it has begun a global early‑stage trial of CR‑001 for advanced solid tumors
CR‑001 is an experimental cancer drug designed to help the immune system attack tumors and block blood supply, CBIO says
Co says study will test safety and how the drug moves and acts in the body before checking for early signs of tumor shrinkage
Trial to enroll up to 290 patients across the U.S., Europe and Asia Pacific; initial data expected in early 2027, CBIO says
Co says it has granted China-based cancer‑drug developer Sichuan Kelun-Biotech exclusive rights to develop and sell the drug in Greater China
Shares down ~52% in 2025
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Eurozone Inflation Gradually Recedes Will ECB Rate-Cut Window Open Again? 2026 Euro Exchange Rate Trend Forecast
TradingKey - After enduring three consecutive years of "high prices, high interest rates, high debt, and low growth," the Eurozone economy is finally demonstrating resilience through a moderate recovery. Currently, the European Central Bank (ECB) faces the ultimate test of maintaining the status quo versus implementing "preemptive rate cuts." Euro exchange rate volatility, inflation trends, and the economic outlook have become the primary focus for investors and financial enthusiasts when allocating overseas assets and capitalizing on currency opportunities.TradingKey
11 hours ago
AMD Stock Price Prediction 2030: Can AMD Narrow Nvidia’s AI Lead?
TradingKey - In the past couple of years, the semiconductor industry has experienced a major change. One question that investors still have is whether or not AMD (AMD) will be able to keep up with Nvidia (NVDA) as far as AI is concerned. What is the possible future of AMD's stock through 2026 and beTradingKey
15 hours ago
Bitcoin Price Prediction 2029-2035: Institutional Accumulation and the U.S. Treasury’s Strategic Reserve Pivot
Explore the 2026 Bitcoin landscape: From the U.S. Strategic Reserve and Michael Saylor’s $75B war chest to Cathie Wood’s 2030 forecast. Is BTC the new Digital Gold?TradingKey
Fri, Feb 13
This $1 Trillion AI Stock Is Getting Ready for 2026: Is Meta a Good Buy?
When ads and commerce are factored in, Meta is building a long-term platform—in Augmented Reality and smart glasses — to get us closer to the future of AI. This device hardware business is less profitable than ads right now, but it could grow the company’s ecosystem and open up new ways for it to maTradingKey
Thu, Feb 12
